questionsmedicales.fr
Maladies cardiovasculaires
Maladies vasculaires
Embolie et thrombose
Thrombose
Thrombose veineuse
Syndrome de Budd-Chiari
Syndrome de Budd-Chiari : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Syndrome de Budd-Chiari : Questions médicales les plus fréquentes",
"headline": "Syndrome de Budd-Chiari : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Syndrome de Budd-Chiari : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-11",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Syndrome de Budd-Chiari"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Thrombose veineuse",
"url": "https://questionsmedicales.fr/mesh/D020246",
"about": {
"@type": "MedicalCondition",
"name": "Thrombose veineuse",
"code": {
"@type": "MedicalCode",
"code": "D020246",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C14.907.355.830.925"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Syndrome de Budd-Chiari",
"alternateName": "Budd-Chiari Syndrome",
"code": {
"@type": "MedicalCode",
"code": "D006502",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None Shalimar",
"url": "https://questionsmedicales.fr/author/None%20Shalimar",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India."
}
},
{
"@type": "Person",
"name": "Akash Shukla",
"url": "https://questionsmedicales.fr/author/Akash%20Shukla",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, 400012, India."
}
},
{
"@type": "Person",
"name": "Joseph J Alukal",
"url": "https://questionsmedicales.fr/author/Joseph%20J%20Alukal",
"affiliation": {
"@type": "Organization",
"name": "Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Talan Zhang",
"url": "https://questionsmedicales.fr/author/Talan%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Paul J Thuluvath",
"url": "https://questionsmedicales.fr/author/Paul%20J%20Thuluvath",
"affiliation": {
"@type": "Organization",
"name": "Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Circulating microRNAs in gallbladder cancer: Is serum assay of diagnostic value?",
"datePublished": "2023-01-16",
"url": "https://questionsmedicales.fr/article/36682281",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.prp.2023.154320"
}
},
{
"@type": "ScholarlyArticle",
"name": "Circulating microRNAs associated with gestational diabetes mellitus: useful biomarkers?",
"datePublished": "2022-12-13",
"url": "https://questionsmedicales.fr/article/36346274",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1530/JOE-22-0170"
}
},
{
"@type": "ScholarlyArticle",
"name": "Circulating microRNAs in cellular and antibody-mediated heart transplant rejection.",
"datePublished": "2022-06-28",
"url": "https://questionsmedicales.fr/article/35872109",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.healun.2022.06.019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Circulating microRNAs predict recurrence and death following venous thromboembolism.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37481073",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtha.2023.07.010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Circulating MicroRNAs and myocardial involvement severity in chronic Chagas cardiomyopathy.",
"datePublished": "2022-08-08",
"url": "https://questionsmedicales.fr/article/36004323",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fcimb.2022.922189"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies cardiovasculaires",
"item": "https://questionsmedicales.fr/mesh/D002318"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies vasculaires",
"item": "https://questionsmedicales.fr/mesh/D014652"
},
{
"@type": "ListItem",
"position": 4,
"name": "Embolie et thrombose",
"item": "https://questionsmedicales.fr/mesh/D016769"
},
{
"@type": "ListItem",
"position": 5,
"name": "Thrombose",
"item": "https://questionsmedicales.fr/mesh/D013927"
},
{
"@type": "ListItem",
"position": 6,
"name": "Thrombose veineuse",
"item": "https://questionsmedicales.fr/mesh/D020246"
},
{
"@type": "ListItem",
"position": 7,
"name": "Syndrome de Budd-Chiari",
"item": "https://questionsmedicales.fr/mesh/D006502"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Syndrome de Budd-Chiari - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Syndrome de Budd-Chiari",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Syndrome de Budd-Chiari",
"description": "Comment diagnostiquer le syndrome de Budd-Chiari ?\nQuels tests sanguins sont utiles ?\nQuels signes cliniques indiquent ce syndrome ?\nL'échographie Doppler est-elle utile ?\nQuand envisager une biopsie hépatique ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Circulating+MicroRNA&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Syndrome de Budd-Chiari",
"description": "Quels sont les symptômes courants ?\nLa douleur abdominale est-elle fréquente ?\nQu'est-ce que l'ascite ?\nLa jaunisse est-elle un symptôme ?\nPeut-on avoir des symptômes asymptomatiques ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Circulating+MicroRNA&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Syndrome de Budd-Chiari",
"description": "Comment prévenir le syndrome de Budd-Chiari ?\nLes anticoagulants peuvent-ils prévenir ce syndrome ?\nQuelles habitudes de vie adopter ?\nLes vaccinations sont-elles importantes ?\nFaut-il surveiller les maladies hépatiques ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Circulating+MicroRNA&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Syndrome de Budd-Chiari",
"description": "Quels traitements sont disponibles ?\nQuand utiliser des anticoagulants ?\nQu'est-ce qu'une procédure endovasculaire ?\nQuand envisager une transplantation hépatique ?\nY a-t-il des traitements symptomatiques ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Circulating+MicroRNA&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Syndrome de Budd-Chiari",
"description": "Quelles sont les complications possibles ?\nL'insuffisance hépatique est-elle fréquente ?\nQu'est-ce que l'hypertension portale ?\nPeut-on avoir des complications à long terme ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Circulating+MicroRNA&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Syndrome de Budd-Chiari",
"description": "Quels sont les principaux facteurs de risque ?\nL'obésité augmente-t-elle le risque ?\nLes maladies hépatiques sont-elles un risque ?\nLes contraceptifs oraux sont-ils un facteur ?\nLe tabagisme influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=Circulating+MicroRNA&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer le syndrome de Budd-Chiari ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'échographie, l'IRM et des tests sanguins pour évaluer la fonction hépatique."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent les marqueurs de la fonction hépatique et les tests de coagulation."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent ce syndrome ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent l'ascite, la douleur abdominale et l'hypertrophie du foie."
}
},
{
"@type": "Question",
"name": "L'échographie Doppler est-elle utile ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet d'évaluer le flux sanguin dans les veines hépatiques et de détecter des obstructions."
}
},
{
"@type": "Question",
"name": "Quand envisager une biopsie hépatique ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie peut être envisagée si le diagnostic est incertain ou pour évaluer des lésions hépatiques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, douleur abdominale, jaunisse et ascite."
}
},
{
"@type": "Question",
"name": "La douleur abdominale est-elle fréquente ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur abdominale est un symptôme fréquent, souvent localisée dans la partie supérieure droite."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que l'ascite ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'ascite est l'accumulation de liquide dans la cavité abdominale, souvent causée par une hypertension portale."
}
},
{
"@type": "Question",
"name": "La jaunisse est-elle un symptôme ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la jaunisse, due à une accumulation de bilirubine, est un symptôme courant du syndrome."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes asymptomatiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent être asymptomatiques, surtout dans les formes chroniques."
}
},
{
"@type": "Question",
"name": "Comment prévenir le syndrome de Budd-Chiari ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut la gestion des facteurs de risque comme les troubles de la coagulation et l'obésité."
}
},
{
"@type": "Question",
"name": "Les anticoagulants peuvent-ils prévenir ce syndrome ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anticoagulants peuvent prévenir les thromboses chez les patients à risque."
}
},
{
"@type": "Question",
"name": "Quelles habitudes de vie adopter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter une alimentation équilibrée, faire de l'exercice et éviter le tabac sont bénéfiques."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, se faire vacciner contre l'hépatite peut réduire le risque de complications hépatiques."
}
},
{
"@type": "Question",
"name": "Faut-il surveiller les maladies hépatiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, surveiller les maladies hépatiques et les troubles de la coagulation est crucial pour la prévention."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des anticoagulants, des procédures endovasculaires et, dans certains cas, une transplantation hépatique."
}
},
{
"@type": "Question",
"name": "Quand utiliser des anticoagulants ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticoagulants sont utilisés pour traiter les thromboses veineuses hépatiques et prévenir les complications."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une procédure endovasculaire ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une intervention pour débloquer les veines hépatiques, souvent par angioplastie ou stenting."
}
},
{
"@type": "Question",
"name": "Quand envisager une transplantation hépatique ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La transplantation est envisagée en cas d'insuffisance hépatique sévère ou de complications irréversibles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements symptomatiques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements symptomatiques comme les diurétiques peuvent aider à gérer l'ascite."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance hépatique, la thrombose et l'hypertension portale."
}
},
{
"@type": "Question",
"name": "L'insuffisance hépatique est-elle fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'insuffisance hépatique est une complication grave pouvant survenir dans ce syndrome."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que l'hypertension portale ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension portale est une augmentation de la pression dans la veine porte, causée par l'obstruction."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications à long terme comme la cirrhose peuvent se développer si non traitées."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un traitement précoce et une surveillance régulière."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent les troubles de la coagulation, l'obésité, et certaines maladies hépatiques."
}
},
{
"@type": "Question",
"name": "L'obésité augmente-t-elle le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est un facteur de risque connu pour le syndrome de Budd-Chiari."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques sont-elles un risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies hépatiques, comme la cirrhose, augmentent le risque de ce syndrome."
}
},
{
"@type": "Question",
"name": "Les contraceptifs oraux sont-ils un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation prolongée de contraceptifs oraux peut augmenter le risque de thrombose."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut contribuer à des problèmes vasculaires, augmentant le risque de thrombose."
}
}
]
}
]
}
The microRNAs (miRNAs) in circulation could serve as biomarkers for cancer detection. Gallbladder carcinoma (GBC) is mostly asymptomatic; therefore, using microRNAs (miRNAs) as an early diagnostic bio...
Different types of small non-coding RNAs, especially miRNAs, may be found in the circulation, either protein-bound or enclosed in extracellular vesicles. During gestation, and particularly during gest...
Noninvasive monitoring of heart allograft health is important to improve clinical outcomes. MicroRNAs (miRs) are promising biomarkers of cardiovascular disease and limited studies suggest they can be ...
The Genomic Research Alliance for Transplantation (GRAfT) is a multicenter prospective cohort study that phenotyped heart transplant patients from 5 mid-Atlantic centers. Patients who had no history o...
The GRAfT cohort had a median age of 52 years, with 35% females and 45% Black patients. Between GRAfT and Stanford, we included 157 heart transplant patients: 108 controls and 49 with rejection (50 AC...
We identified novel miRs that had excellent performance to noninvasively diagnose acute rejection after heart transplantation. Once rigorously validated, the unique clinical ACR and AMR scores usher i...
Recurrent events frequently occur after venous thromboembolism (VTE) and remain difficult to predict based on established genetic, clinical, and proteomic contributors. The role of circulating microRN...
To identify circulating miRNAs predictive of recurrent VTE or death, and to interpret their mechanistic involvement....
Data from 181 participants of a cohort study of acute VTE and 302 individuals with a history of VTE from a population-based cohort were investigated. Next-generation sequencing was performed on EDTA p...
A total of 1950 miRNAs were detected across cohorts after postprocessing. In the discovery cohort, 50 miRNAs were associated with recurrent VTE or death (cross-validated C-index, 0.65). A weighted miR...
Circulating miRNAs predicted the risk of recurrence or death after VTE over several years, both in the acute and chronic phases....
Chronic Chagas Cardiomyopathy (CCM) is characterized by a unique pathophysiology in which inflammatory, microvascular and neuroendocrine processes coalesce in the development of one of the most severe...
Patients with CCM and reduced ejection fraction were included in a prospective exploratory cohort study. We assessed the association of natural log-transformed values of six circulating microRNAs (miR...
Seventy-four patients were included (59% males, median age: 64 years). After adjustment for age, sex, body mass index, and heart failure medications, only increasing miR-223-5p relative expression lev...
The present study found an association between miR-223-5p and clinical parameters of CCM, with signaling pathways related to receptor tyrosine kinases as a potential mechanism linking low levels of mi...
MicroRNA (miRNA) expression dysregulations in pancreatic ductal adenocarcinoma (PDAC) have been studied widely for their diagnostic and prognostic utility. By the use of bioinformatics-based methods, ...
Transient ischemic attack (TIA) refers to a momentary neurologic deficit caused by focal cerebral, spinal or retinal ischemic insult. TIA is associated with a high risk of impending acute ischemic str...
miR-122 is the most abundant microRNA (miRNA) in the liver; it regulates several genes mainly involved in cell metabolism and inflammation. Host factors, diet, metabolic disorders and viral infection ...
MicroRNAs (miRs) are small noncoding RNAs that regulate gene expression and are emerging as powerful indicators of diseases. MiRs are secreted in blood plasma and thus may report on systemic aberratio...
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy. Pathogenic germline variation in genes encoding the sarcomere is the predominant cause of disease. However diagnostic featu...
We performed arrays for 381 miRNAs using serum from HCM sarcomere variant carriers with and without a diagnosis of HCM and healthy controls. To identify differentially expressed circulating miRNAs bet...
Of 57 sarcomere variant carriers, 25 had clinical HCM and 32 had subclinical HCM with normal left ventricular wall thickness (21 with early phenotypic manifestations and 11 with no discernible phenoty...
Circulating miRNAs may augment the clinical stratification of HCM and improve understanding of the transition from health to disease in sarcomere gene variant carriers....